Skip to main content

Table 2 Preoperative demographics of patients

From: Systematic review of first-in-human and early phase clinical trials for surgically implantable biological mitral valve substitutes

References

Gender

Range of patient age (in years)

Average patient age (in years)

Preoperative NYHA Class

Associated/concomitant procedures

I

II

III

IV

Relland [9]

NA

NA

NA

NA

NA

Jamieson [10]

NA

NA

NA

NA

NA

Jamieson [11]

527F, 745 M

9–91

67

NA

NA

Williams [12]

100F, 67 M

5–78

39

NA

NA

Loisance [13]

82F, 84 M

14–83

58 ± 13

6.02%

 

69.90%

33.1% (55)

Bortolotti [14]

NA

29–76

59 ± 8

 

5.38%

88.50%

6.15%

18.4% (24)

Garcia [15]

32F, 8 M

32–81

65.6

  

76%

31% (12)

Wheatley [16]

25F, 6 M

38–69

57.6 ± 9.9

3.23%

38.70%

54.80%

3.23%

22.6% (7)

Vermeulen [17]

945F, 520 M

NA

58.6 ± 14.8

 

6.90%

60.00%

31.60%

11% (48)

Mohr [18]

36F, 16 M

NA

68 ± 8.5

Average 3.1 ± 0.6

 

Fradet [19]

194F, 172 M

17–84

68

  

79.20%

42.30%

Hiremath [20]

18F, 12 M

18–72

48.57 ± 12.63

  

96.67%

3.33%

33.3% (10)

Firstenberg [21]

33F, 36 M

 

72.3 ± 5.5

  

84%

 

Folliguet [22]

68F, 32 M

41–84

69

 

14.40%

49.50%

32.10%

31% (86)

Eichinger [23]

261F, 300 M

  

0.00%

19.00%

58.00%

23.00%

64% (64)

Masters [24]

78F, 60 M

38–85

72 ± 0.8

14%

12%

43%

21%

67% (92)

Pomerantz [25]

320F, 226 M

   

2.20%

55.90%

41.90%

32.7% (179)

Frater [26]

126F, 49 M

12–87

46

  

62.5%

16.50%

45.7% (80)

Riess [27]

33F, 14 M

41–84

67

0%

36.20%

59.60%

4.30%

 

Jamieson [28]

98F, 77 M

44.5–91.4

72.2 ± 8.9

  

61.70%

 

Loor [29]

34F, 36 M

29–88

68

57%

43%

83% (58)

Celiento [30]

36F, 64 M

 

73 ± 10

6%

9%

61%

24%

41% (41)

  1. NB: italic: Older First-in-man (FIM); bold: FIM; bolditalic: Early Clinical trials; NYHA = New York Heart Association; NA = Not applicable; M = Male, F = Female